AUGEAS: Study in Diabetes Mellitus Patients Without Prior Myocardial Infarction or Stroke Undergoing Elective Percutaneous Coronary Intervention.

Sponsor

Region Skane (Other)

Overall Status

Withdrawn

CT.gov ID

NCT04069234

Collaborator

IHF GmbH - Institut für Herzinfarktforschung (Other), Hippocrates Research (Other), IRW consulting AB (Other), AstraZeneca (Industry)

Enrollment

Arms

30.5

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

This study is designed to test the hypothesis that ticagrelor is superior to clopidogrel, in improving coronary microvascular function, as measured by coronary flow reserve (CFR) in patients with T2DM at high risk of cardiovascular (CV) events undergoing elective PCI.

Condition or Disease	Intervention/Treatment	Phase
Diabetes Mellitus Microvascular Coronary Artery Disease	Drug: Ticagrelor Drug: Clopidogrel	Phase 3

Detailed Description

Coronary artery disease (CAD) can be divided into macrovascular and microvascular disease, both different manifestations of atherosclerosis. Macrovascular CAD, i.e. obstructive CAD of epicardial coronary arteries have traditionally been the focus of CAD treatment. Microvascular circulation, on the other hand, consists of arterioles (diameter <100 μm) within myocardium and abnormalities in this arterial bed may also impair myocardial perfusion and result in ischaemia. An indication of microvascular disease can be achieved with coronary flow reserve (CFR) which is an integrated measure of flow through both large epicardial arteries and coronary microcirculation. CFR measurement is the ratio of resting coronary artery mean diastolic flow velocity in comparison to hyperaemic coronary artery mean diastolic flow velocity, where hyperaemia is often induced with pharmacologic agent such as adenosine infusion. CFR of the left anterior descending (LAD) coronary artery during pharmacologic stress echocardiography has been found to provide effective prognostic information in patients with known or suspected CAD. This seems evident across patient populations, such as those with diabetes or chronic kidney disease, or older age. Particularly, a CFR <2.0 has been associated with markedly increased cardiovascular (CV) risk in an unselected patient population.

Ticagrelor primary mode of action is as a direct acting reversibly binding P2Y12 antagonist inhibiting ADP-induced platelet activation. However, ticagrelor has also been shown to increase extracellular adenosine concentration by inhibition of the equilibrative nucleoside transporter 1 (ENT1). Adenosine has been described to have a number of physiological effects including vasodilation, anti-inflammation, anti-platelet and cardioprotective effects and ticagrelor has been shown to enhance many of these adenosine-induced effects in animal models and in man. These adenosine-mediated effects may be beneficial to CAD patients and potentially impact coronary microvascular function and contribute to the clinical profile of ticagrelor. So far only one study has explored ticagrelor effect on coronary microvascular function. They showed, by using rubidium 82 positron emission tomography/computed tomography, that ticagrelor could improve local CFR compared to clopidogrel in CAD patients specifically in those regions that before treatment had impaired CFR (<2.5). CFR has been shown to be a strong independent predictor in diabetic patients with suspected coronary disease for future coronary events and survival.

The ongoing THEMIS study is designed to test the hypothesis that ticagrelor is superior to placebo, in prevention of major CV events, as measured by time to first event of the composite of CV death, MI, or stroke in patients with T2DM at high risk of CV events.

Patients undergoing elective PCI are excluded from the THEMIS study as these patients are treated with clopidogrel plus aspirin. The current study is designed to fill this data gap by generating clinically meaningful data with ticagrelor in THEMIS-like patients undergoing elective PCI.

Study Design

Study Type:

Interventional

Actual Enrollment :

0 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Single (Outcomes Assessor)

Primary Purpose:

Treatment

Official Title:

30-d Rand, Eval-blind, Controlled, Multi-centre, Parallel, ph III Study to Evaluate Effect of a Low Maint Dose Ticagrelor Regimen vs Standard Dose Clopidogrel on Coronary Flow Reserve in DM Patients With Impaired Microvascular Function Without Prior MI or Stroke Undergoing ePCI.

Anticipated Study Start Date :

Sep 15, 2019

Anticipated Primary Completion Date :

Oct 15, 2021

Anticipated Study Completion Date :

Mar 31, 2022

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Ticagrelor ticagrelor 60mg BID for 30 Days and ASA 75 - 150 mg once daily	Drug: Ticagrelor ticagrelor 60 mg BID for 30 days
Active Comparator: Clopidogrel clopidogrel 75mg OD for 30 Days and ASA 75 - 150 mg once daily	Drug: Clopidogrel clopidogrel 75mg OD for 30 Days

Arm

Intervention/Treatment

Experimental: Ticagrelor

ticagrelor 60mg BID for 30 Days and ASA 75 - 150 mg once daily

Drug: Ticagrelor

ticagrelor 60 mg BID for 30 days

Active Comparator: Clopidogrel

clopidogrel 75mg OD for 30 Days and ASA 75 - 150 mg once daily

Drug: Clopidogrel

clopidogrel 75mg OD for 30 Days

Outcome Measures

Primary Outcome Measures

Coronary Flow Velocity Reserve (CFR) [30+/- 3 days after randomization]
Difference in mean of individual absolute change from baseline to 30 days in Coronary Flow Velocity Reserve (CFR) in the mid-distal segment of the left anterior descending (LAD) coronary artery under adenosine infusion measured by Transthoracic Doppler Echocardiography (TDE) between the two arms

Secondary Outcome Measures

Coronary flow parameter-LAD hyperemic mean diastolic flow velocity [30+/- 3 days after randomization]
Difference in mean of individual absolute change from baseline at 30 days in: - LAD hyperemic mean diastolic flow velocity
Coronary flow parameter-LAD resting mean diastolic flow velocity [30+/- 3 days after randomization]
Difference in mean of individual absolute change from baseline at 30 days - LAD resting mean diastolic flow velocity

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Provision of informed consent prior to any study specific procedures
Men or women ≥18 years of age
Diagnosed with T2DM defined as treatment with ongoing glucose lowering drug (oral medications and/or insulin) for at least 1 month
Presence of CAD undergoing elective PCI
Impaired coronary microvascular function post PCI as defined by a CFR ≤2.5 (as per local reading)
TIMI 3 flow post PCI

Exclusion Criteria:

Previous MI defined as a documented hospitalization with a final diagnosis of spontaneous MI (with the exception of definite secondary MI [e.g., due to coronary revascularization procedure, profound hypotension, hypertensive emergency, tachycardia, or profound anemia]).
Previous stroke (transient ischemic attack [TIA] is not included in the stroke definition)
Use of an intravenous antiplatelet therapy (i.e., cangrelor or GPI) during PCI
On treatment with clopidogrel, prasugrel, or ticagrelor due to a prior acute major CV event (MI or stroke) (on treatment with clopidogrel due to prior vascular intervention not secondary to a major CV event is allowed)
Planned use of aspirin treatment at doses >150 mg od
Anticipated concomitant oral or intravenous therapy with strong cytochrome P450 3A4 (CYP3A4) inhibitors or CYP3A4 substrates with narrow therapeutic indices that cannot be stopped for the course of the study:
Strong CYP3A4 inhibitors: ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin (but not erythromycin or azithromycin), nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir
CYP3A4 substrates with narrow therapeutic index: quinidine, simvastatin at doses

40 mg daily or lovastatin at doses >40 mg daily

Hypersensitivity to ticagrelor or any of its excipients
Need for chronic oral anticoagulant therapy or chronic low-molecular-weight heparin
Patients with known bleeding diathesis or coagulation disorder
History of intracerebral bleed at any time, gastrointestinal (GI) bleed within the past 6 months prior to randomization, or major surgery within 30 days prior to randomization
Increased risk of bradycardic events (e.g., known sick sinus syndrome, second or third-degree AV block or previous documented syncope suspected to be due to bradycardia) unless treated with a pacemaker
Known severe liver disease (e.g., ascites and/or clinical signs of coagulopathy)
Renal failure requiring dialysis
Known platelet count <145 x109 platelets/L
Known hemoglobin <9 g/dL
Women of child-bearing potential (WOCBP)*, who are not willing to use a method of contraception that is considered highly reliable** per CTFG (Clinical Trial Facilitation Group), OR who have a positive pregnancy test at enrolment or randomization OR women who are breast-feeding
Inability of the patient to understand and/or comply with study procedures and/or follow up, in the opinion of the investigator, OR any conditions that, in the opinion of the investigator, may render the patient unable to complete the study
Life expectancy of less than 6 month based on investigator's judgement
Participation in another clinical study with an investigational (defined as non-approved) product, if taken within five half-lives or 28 days prior to the first administration of the trial medication, whichever is longer
Previous randomization in the present study
Severe asthma
Hypersensitivity to adenosine or mannitol
Long QT syndrome
Chronic obstructive lung disease, with evidence of bronchospasm
Severe low blood pressure
Unstable angina pectoris
Severe heart failure
Hypovolemia
Treatment with dipyradimol
Increased intracranial pressure * fertile, following menarche until becoming post-menopausal, unless permanently sterile (permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy) ** estrogen/progestogen or progestogen (oral, intravaginal or transdermal administration); intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; vasectomised partner; sexual abstinence